The research service primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing. The study provides key insights into the transforming pharmaceutical value chain, with the adoption of technology and shift towards digitalization of key processes across drug development and manufacturing as well as supply chain and logistics. It also analyzes the dynamics catalyzing growth, profiles organizations promising significant growth opportunities, and outlines innovative industry trends of key participants who play a vital role in the pharmaceutical landscape. Furthermore, the research also highlights the adoption of newer business models by the game-changing companies to adapt to the changing trend of a value-based care model as opposed to the traditional volume-based model.
Key Target Audience:
• Small to mid-sized pharma and biotech companies which need to benchmark their capabilities with respect to the game-changing companies
• Big pharma companies interested in gaining an understanding of the competitive landscape with respect to strategic growth levers
The research service covers the top 5 pharmaceutical companies in the United States (US), based on their industry position. The companies included in the study are Pfizer, Gilead, Johnson & Johnson, Merck & Co., and Amgen. These companies are benchmarked across 5 key growth levers:
• Core areas of focus
• Digital footprint
• Value chain excellence
• Strategic collaborations and partnerships, and
• Beyond the pill services and solutions
The benchmarking across these strategic growth levers would provide insights into their positioning with respect to the changing market landscape as well as measures taken by these companies to align themselves with these changing market needs. Furthermore, there are additional highlights provided on the companies being profiled.
Highlights of the company profiles in